Τίτλος:
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety-five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males. Sixty-seven patients received BV after autologous stem cell transplantation failure, whereas 28 patients were treated with BV without a prior autologous stem cell transplantation, due to advanced age/comorbidities or chemorefractory disease. The median number of prior treatments was 4 and 44% of the patients were refractory to their most recent therapy. The median number of BV cycles was 8 (range, 2-16), and the median time to best response was the fourth cycle. Fifty-seven patients achieved an objective response: twenty-two (23%), a complete response (CR), and 35 patients (37%), a partial, for an overall response rate of 60%. Twelve patients (13%) had stable disease, and the remaining twenty-six (27%) had progressive disease as their best response. At a median follow-up of 11.5 months, median progression-free survival and overall survival were 8 and 26.5 months, respectively. Multivariate analysis showed that chemosensitivity to treatment administered before BV was associated with a significantly increased probability of achieving response to BV (P =.005). Bulky disease (P =.01) and response to BV (P <.001) were significant for progression-free survival, while refractoriness to most recent treatment (P =.04), bulky disease (P =.005), and B-symptoms (P =.001) were unfavorable factors for overall survival. Among the 22 CRs, 5 remain in CR with no further treatment after BV at a median follow-up of 13 months. In conclusion, our data indicate that BV is an effective treatment for R/R HL patients even outside clinical trials. Whether BV can cure a fraction of patients remains to be seen. © 2017 The Authors Hematological Oncology Published by John Wiley & Sons Ltd
Συγγραφείς:
Angelopoulou, M.K.
Vassilakopoulos, T.P.
Batsis, I.
Sakellari, I.
Gkirkas, K.
Pappa, V.
Giannoulia, P.
Apostolidis, I.
Apostolopoulos, C.
Roussou, P.
Panayiotidis, P.
Dimou, M.
Kyrtsonis, M.-C.
Palassopoulou, M.
Vassilopoulos, G.
Moschogiannis, M.
Kalpadakis, C.
Margaritis, D.
Spyridonidis, A.
Michalis, E.
Anargyrou, K.
Repousis, P.
Hatzimichael, E.
Bousiou, Z.
Poulakidas, E.
Grentzelias, D.
Harhalakis, N.
Pangalis, G.A.
Anagnostopoulos, A.
Tsirigotis, P.
Περιοδικό:
Journal of Hematology & Oncology
Εκδότης:
John Wiley and Sons Ltd
Λέξεις-κλειδιά:
brentuximab vedotin; antibody conjugate; brentuximab vedotin, adult; allogeneic stem cell transplantation; Article; autologous stem cell transplantation; cancer chemotherapy; cancer radiotherapy; cancer recurrence; cancer survival; chemosensitivity; disease control; disease exacerbation; female; follow up; Hodgkin disease; human; major clinical study; male; overall survival; patient history of chemotherapy; priority journal; progression free survival; retrospective study; salvage therapy; treatment failure; clinical trial; Hodgkin disease; mortality; multicenter study; pathology; prognosis; survival analysis; treatment outcome, Adult; Female; Hodgkin Disease; Humans; Immunoconjugates; Male; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome
